Jennifer Buell - Sep 9, 2025 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
Chief Executive Officer
Signature
By: /s/ Christine Klaskin, Attorney-in-Fact
Stock symbol
INKT
Transactions as of
Sep 9, 2025
Transactions value $
$279,997
Form type
4
Date filed
9/11/2025, 04:46 PM
Previous filing
May 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Buell Jennifer Chief Executive Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK By: /s/ Christine Klaskin, Attorney-in-Fact 2025-09-11 0001711184
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INKT Common Stock Award $280K +18.2K +76.97% $15.36 41.9K Sep 9, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INKT Stock Option (Right to Buy) Award $0 +50K $0.00 50K Sep 9, 2025 Common Stock 50K $15.36 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the executive's 2024 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on October 9, 2025.
F2 $15.36 was the fair market value of MiNK Therapeutics, Inc. Common Stock on September 9, 2025, the stock issuance date.
F3 The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the date of grant, with the remainder vesting in eight equal quarterly installments thereafter, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.